Publications by authors named "M D Holida"

Claim this Profile
A
A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.
Myrl Holida, Aleš Linhart, Antonio Pisani, Nicola Longo, François Eyskens

J Inherit Metab Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective characterization of early symptom onset and progression in young pediatric patients with variants in the gene across 5 years: Longitudinal data from the Fabry MOPPet Study.
D A Laney, M F Houde, A L Foley, D S Peck, A M Atherton, M D Holida

Genet Med Open· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Eric L Wallace, Ozlem Goker-Alpan, William R Wilcox, Myrl Holida, John Bernat

J Med Genet· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease.
Derralynn Hughes, Derlis Gonzalez, Gustavo Maegawa, John A Bernat, Myrl Holida

Genet Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease.
Behzad Najafian, Aurelio Silvestroni, Alexey Sokolovskiy, Camilla Tøndel, Einar Svarstad, Myrl D Holida

Kidney Int· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis